Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Eva, Muehlhofer"'
Autor:
Connie N. Hess, Iris Baumgartner, Sonia S. Anand, Mark R. Nehler, Manesh R. Patel, E. Sebastian Debus, Michael Szarek, Warren Capell, Eva Muehlhofer, Scott D. Berkowitz, Lloyd P. Haskell, Rupert M. Bauersachs, Marc P. Bonaca, Judith Hsia
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 12 (2022)
Background Despite high female prevalence of peripheral artery disease (PAD), little is known about sex‐based outcomes after lower extremity revascularization (LER) for symptomatic PAD. The effects of rivaroxaban according to sex following LER have
Externí odkaz:
https://doaj.org/article/e206edcaf2794bc898a22f84d5fb18a2
Autor:
Mohammad Qadura, Muzammil H. Syed, Sonia Anand, Jackie Bosch, Stuart Connolly, Victor Aboyans, Eva Muehlhofer, Salim Yusuf, John Eikelboom
Publikováno v:
Atherosclerosis. 372:41-47
Autor:
Kelley R.H. Branch, Jeffrey L. Probstfield, Jackie Bosch, Deepak L. Bhatt, Aldo P. Maggioni, Eva Muehlhofer, Alvaro Avezum, Petr Widimsky, Stuart J. Connolly, Quilong Yi, Olga Shestakovska, Salim Yusuf, John W. Eikelboom
Publikováno v:
American Heart Journal. 258:60-68
Autor:
Marc P. Bonaca, Michael Szarek, E. Sebastian Debus, Mark R. Nehler, Manesh R. Patel, Sonia S. Anand, Eva Muehlhofer, Scott D. Berkowitz, Lloyd P. Haskell, Rupert M. Bauersachs
Publikováno v:
Clinical Cardiology. 45:1143-1146
The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery
Autor:
Scott D. Berkowitz, Rupert M. Bauersachs, Michael Szarek, Mark R. Nehler, E. Sebastian Debus, Manesh R. Patel, Sonia S. Anand, Warren H. Capell, Connie N. Hess, Judy Hsia, Nicholas J. Leeper, David Brasil, Lajos Mátyás, Rafael Diaz, Marianne Brodmann, Eva Muehlhofer, Lloyd P. Haskell, Marc P. Bonaca
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:1193-1205
Vascular disease burden after lower extremity revascularization (LER) comprises more than the first event, more vascular beds than the local arteries, and more than one clinical event type.Assess total arterial and venous thrombotic burden after LER
Autor:
Sonia S. Anand, Judith Hsia, Marianne Brodmann, Marc P. Bonaca, Henrik Sillesen, Nicholas J. Leeper, E. Sebastian Debus, Eva Muehlhofer, Connie N. Hess, Joshua A. Beckman, Peter Habertheuer, Rafael Diaz, Rupert Bauersachs, Michael Szarek, Scott D. Berkowitz, Manesh R. Patel, Richard J. Powell, Lloyd Haskell, Mark R. Nehler, Warren H. Capell
Publikováno v:
Hess, C N, Debus, E S, Nehler, M R, Anand, S S, Patel, M R, Szarek, M, Capell, W H, Hsia, J, Beckman, J A, Brodmann, M, Diaz, R, Habertheuer, P, Leeper, N J, Powell, R J, Sillesen, H, Muehlhofer, E, Berkowitz, S D, Haskell, L P, Bauersachs, R M & Bonaca, M P 2021, ' Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization : Insights From VOYAGER PAD ', Circulation, vol. 144, no. 23, pp. 1831-1841 . https://doi.org/10.1161/CIRCULATIONAHA.121.055146
Background: Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Previous lower extremity revascularization (LER) is associated wi
Autor:
Marc P. Bonaca, Eric A. Secemsky, Mark R. Nehler, Rupert Bauersachs, Robert W. Yeh, Warren H. Capell, Manesh R. Patel, Sonia S. Anand, Eva Muehlhofer, Lloyd Haskell, Nicholas Govsyeyev, Connie N. Hess, Taylor Brackin, William R. Hiatt, E. Sebastian Debus, Joshua A. Beckman, Fabrizio Fanelli, Laura Mauri, Scott D. Berkowitz
Publikováno v:
Journal of the American College of Cardiology. 78:1768-1778
Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety
Autor:
Sebastian Debus, Lloyd Haskell, Marc P. Bonaca, Manesh R. Patel, Eva Muehlhofer, Michael Szarek, Mori J. Krantz, Patrice Nault, Sonia S. Anand, Lajos Mátyás, William R. Hiatt, Rupert Bauersachs, Judith Hsia, Mark R. Nehler, Warren H. Capell, Dainis Krievins, Scott D. Berkowitz, Stefan Stefanov, Connie N. Hess, Taylor Bracken
Publikováno v:
European Heart Journal. 42:4040-4048
Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy
Autor:
Ivan Gudz, Rupert Bauersachs, Voyager Pad Committees, Manesh R. Patel, Scott D. Berkowitz, Michael Szarek, Mark R. Nehler, Kevin Rogers, Lloyd Haskell, Connie N. Hess, Eike Sebastian Debus, William R. Hiatt, Marc P. Bonaca, Marianne Brodmann, Warren H. Capell, Sonia S. Anand, Investigators, Eva Muehlhofer
Publikováno v:
Journal of the American College of Cardiology. 78:317-326
Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb and cardiovascular events. The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Throm
Autor:
Nicholas Govsyeyev, Mark Nehler, Michael S. Conte, Sebastian Debus, Jayer Chung, Walter Dorigo, Ivan Gudz, Dainis Krievins, Joseph Mills, Frans Moll, Lars Norgren, Gabriele Piffaretti, Rick Powell, David Szalay, Henrik Sillesen, Max Wohlauer, Michael Szarek, Rupert M. Bauersachs, Sonia S. Anand, Manesh R. Patel, Warren H. Capell, Nicole Jaeger, Connie N. Hess, Eva Muehlhofer, Lloyd P. Haskell, Scott D. Berkowitz, Marc P. Bonaca
Publikováno v:
Journal of Vascular Surgery. 77:1107-1118.e2
Patients with peripheral artery disease (PAD) requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. VOYAGER PAD demonstrated that rivaroxaban significantly reduced this risk with an overall favo